The Influence of Radiological “Disappearing Lesions” on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy
Table 1
Baseline characteristics of patients corresponding single DLM.
Characteristics
No. 301
Sex
Male
161 (53.5%)
Female
140 (46.5%)
Age () (year)
BMI preoperative () (kg/m2)
CEA preoperative () (ng/ml)
CA 19-9 preoperative () (u/ml)
Tumor site
Colon
175 (58.1%)
Rectum
126 (41.9%)
Simultaneous/metachronous liver metastases
Simultaneous
263 (87.4%)
Metachronous
38 (12.6%)
Extrahepatic metastasis
Yes
136 (45.2%)
No
165 (54.8%)
Conversion therapy regimens
Chemotherapy alone
162 (53.8%)
Targeted therapy alone
10 (3.3%)
Chemotherapy combined targeting
129 (42.9%)
Lymph node metastasis
Yes
136 (45.2%)
No
66 (21.9%)
Data loss
99 (32.95%)
Site of liver metastases
S1
6 (2.0%)
S2
24 (8.0%)
S3
25 (8.3%)
S4
34 (11.3%)
S5
40 (13.3%)
S6
41 (13.6%)
S7
57 (18.9%)
S8
74 (24.6%)
Size of liver metastases
<5 mm
30 (10.0%)
5-10 mm
100 (33.2%)
>10 mm
171 (56.8%)
Note: Variables are expressed as the or (%). Abbreviations: DLM: disappearing liver metastasis; BMI: body mass index; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 199.
